In8Bio (INAB) Short term Debt (2020 - 2021)
In8Bio's (INAB) quarterly Short term Debt came in at $174000.0 in Q2 2021, little changed quarter-over-quarter from $174000.0 in Q4 2020.
Powered by 
Analysis
In8Bio (INAB) Short term Debt (2020 - 2021) Analysis & Trends
In8Bio has disclosed Short term Debt across 2 years of filings, most recently posting $174000.0 for Q2 2021.
- In Q2 2021, Short term Debt changed N/A year-over-year to $174000.0; the TTM figure through Jun 2021 stood at $174000.0 (changed N/A YoY), while the FY2020 annual figure was $174000.0, changed N/A from the prior year.
- Short term Debt came in at $174000.0 for Q2 2021 at In8Bio, roughly flat from $174000.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $174000.0 in Q4 2020 to a low of $174000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | In8Bio | 21.58 Mn | 21.58 Mn | - |